BioMarin Pharma Q2 revenue beats estimates

BioMarin Pharmaceutical

04/08/2025 21:16

Overview

BioMarin Q2 2025 revenue rises 16% yr/yr, beating analyst expectations

Non-GAAP diluted EPS for Q2 beats estimates, rising 50% yr/yr

Co completes acquisition of Inozyme, adding BMN 401 to enzyme therapies

Outlook

BioMarin raises full-year 2025 revenue guidance to $3.125 bln-$3.200 bln

Company expects 2025 Non-GAAP EPS of $4.40 to $4.55

BioMarin sees 2025 Non-GAAP operating margin at 33%-34%

Company anticipates limited impact from new tariffs in 2025

Result Drivers

VOXZOGO DEMAND - 20% revenue growth driven by strong global demand and new patient initiations

ENZYME THERAPIES - 15% revenue increase due to patient demand and large government orders

GENERIC COMPETITION - Decline in KUVAN revenues attributed to loss of market exclusivity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$825 mln
$760 mln (23 Analysts)
Q2 Adjusted EPS
Beat
$1.44
$0.83 (17 Analysts)
Q2 EPS
$1.23
Q2 Net Income
$241 mln
Q2 Basic EPS
$1.25


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $95.00, about 38.8% above its August 1 closing price of $58.14

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nPn1lM2B4a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)